Stock Price Forecast

March 18, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading AvroBio Inc chart...

About the Company

clinical stage company focused on delivering step-change cell & gene therapies targeting cancer and rare disease.

Exchange

NASDAQ

Website

avrobio.com

$80M

Total Revenue

95

Employees

$58M

Market Capitalization

104.19

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $AVRO News

Avrobio (NASDAQ: AVRO)

3d ago, source: The Motley Fool

Avrobio, Inc. engages in the development of lentiviral-based gene therapies. It focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat patients with rare ...

AVROBIO Inc

2mon ago, source: CNN

Avrobio, Inc. engages in the development of lentiviral-based gene therapies. It focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat patients with rare ...

New Suit - Securities

20d ago, source: Law

Counsel have not yet appeared for the defendants. The case is 1:24-cv-01493, Garofalo v. AVROBIO Inc. et al.

AVROBIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AVROBIO, Inc. - AVRO

1mon ago, source: Stockhouse

Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of AVROBIO, Inc. (NasdaqGS: AVRO) and Tectonic Therapeutic, Inc. pursuant ...

AVROBIO, Inc. (AVRO) Stock Historical Prices & Data - Yahoo Finance

4d ago, source: Yahoo Finance

*Close price adjusted for splits.**Adjusted close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...

AVROBIO to Explore Strategic Alternatives

19d ago, source: ADVFN

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that it has completed a review of its ...

AVROBIO Announces Positive Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis at the ASGCT 26th Annual Meeting

1mon ago, source: ADVFN

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced follow-up data demonstrating a durable ...

ADVM Adverum Biotechnologies, Inc.

3d ago, source: Seeking Alpha

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM ...

Clarus Ventures III GP, L.P.'s Net Worth

13d ago, source: Benzinga.com

Inc., Entasis Therapeutics Holdings Inc., AVROBIO, Inc., and Forty Seven, Inc.. Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the ...

AVROBIO, Inc. (AVRO)

4d ago, source: Yahoo Finance

*Close price adjusted for splits.**Adjusted close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...